Paradigm Biopharmaceuticals Limited (ASX:PAR)

ASX:PAR Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Operating Revenue	0.02	-	-	0.08	0.02	-
Revenue	0.02	-	-	0.08	0.02	-
Revenue Growth (YoY)	-	-	-	285.52%	-	-
Cost of Revenue	0.03	0.01	0.02	0.14	0.1	-
Gross Profit	-0.01	-0.01	-0.02	-0.06	-0.08	-
Selling, General & Admin	5.36	6.77	7.39	8.85	9.59	2.94
Research & Development	15.95	58.33	52.68	39.01	33.52	14.02
Operating Expenses	21.3	65.1	60.07	47.87	43.1	16.96
Operating Income	-21.31	-65.11	-60.09	-47.93	-43.18	-16.96
Interest Expense	-0.01	-0.01	-0.02	-0.03	-0.04	-0.03
Interest & Investment Income	0.28	0.41	1.4	0.05	0.21	1
Currency Exchange Gain (Loss)	0.04	-0.05	-0.39	0.89	0.31	-
Other Non Operating Income (Expenses)	6.44	6.11	7.09	7.76	8.4	3.7
EBT Excluding Unusual Items	-14.56	-58.65	-52	-39.25	-34.3	-12.3
Other Unusual Items	-	-	0.09	-	-	-
Pretax Income	-14.56	-58.65	-51.91	-39.25	-34.3	-12.3
Net Income	-14.56	-58.65	-51.91	-39.25	-34.3	-12.3
Net Income to Common	-14.56	-58.65	-51.91	-39.25	-34.3	-12.3
Shares Outstanding (Basic)	320	293	250	233	230	201
Shares Outstanding (Diluted)	320	293	250	233	230	201
Shares Change (YoY)	20.89%	17.43%	7.34%	1.21%	14.32%	40.59%
EPS (Basic)	-0.05	-0.20	-0.21	-0.17	-0.15	-0.06
EPS (Diluted)	-0.05	-0.20	-0.21	-0.17	-0.15	-0.06
Free Cash Flow	-23.14	-65.94	-45.19	-32.21	-34.96	-10.22
Free Cash Flow Per Share	-0.07	-0.23	-0.18	-0.14	-0.15	-0.05
Gross Margin	-65.89%	-	-	-81.45%	-	-
Operating Margin	-127623.81%	-	-	-60498.78%	-210124.38%	-
Profit Margin	-87171.95%	-	-	-49542.54%	-166896.27%	-
Free Cash Flow Margin	-138571.38%	-	-	-40650.90%	-170122.95%	-
EBITDA	-21.17	-64.97	-59.93	-47.74	-43.13	-16.88
D&A For EBITDA	0.14	0.15	0.15	0.19	0.05	0.08
EBIT	-21.31	-65.11	-60.09	-47.93	-43.18	-16.96

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.